Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1Lymphoid 1Genitourinary 1Gastrointestinal 1CNS 1

Conditions

Prostatic Neoplasms 20Lung Neoplasms 18Glioma 13Neoplasm Metastasis 11Carcinoma, Non-Small-Cell Lung 11Breast Neoplasms 11Urinary Bladder Neoplasms 10Pancreatic Neoplasms 10Multiple Myeloma 10Lymphoma 10Squamous Cell Carcinoma of Head and Neck 9Mouth Neoplasms 9Colorectal Neoplasms 8Carcinoma, Renal Cell 8Ovarian Neoplasms 7Oropharyngeal Neoplasms 7Melanoma 7Laryngeal Neoplasms 7Glioblastoma 7Carcinoma, Hepatocellular 7Carcinoma 7Wilms Tumor 6Sarcoma 6Neuroblastoma 6Nasopharyngeal Carcinoma 6Medulloblastoma 6Lymphoma, Non-Hodgkin 6Fallopian Tube Neoplasms 6Triple Negative Breast Neoplasms 5Rhabdoid Tumor 5

Interventions

erdafitinib 1X-Rays 1Specimen Handling 1Phantoms, Imaging 1Nuclear Medicine Department, Hospital 1Magnetic Resonance Spectroscopy 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Familial ependymoma × Magnetic Resonance Spectroscopy × 30 days × Clear all
NCT03210714 2026-06-01

Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
20 enrolled 10 charts
CNSGastrointestinalGenitourinaryLymphoidMyeloid

Familial ependymoma, Ependymoma, Glioma, Histiocytosis, Langerhans-Cell, Lymphoma, Non-Hodgkin, Medulloblastoma, Wilms Tumor, Neuroblastoma, Central Nervous System Neoplasms, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡